Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

被引：0
作者：
W Chua
D Goldstein
C K Lee
H Dhillon
M Michael
P Mitchell
S J Clarke
B Iacopetta
机构：
[1] Sydney Cancer Centre,Department of Medical Oncology
[2] Concord Repatriation General Hospital,Department of Medical Oncology
[3] Prince of Wales Hospital,Division of Haematology and Medical Oncology
[4] NHMRC Clinical Trials Centre,Department of Medical Oncology
[5] Centre of Medical Psychology and Evidence-based Decision-Making,undefined
[6] University of Sydney,undefined
[7] Peter MacCallum Cancer Centre,undefined
[8] Austin Hospital,undefined
[9] School of Surgery,undefined
[10] University of Western Australia,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
colorectal cancer; metastatic; chemotherapy; predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：998 / 1004
页数：6
相关论文
共 50 条
  • [31] Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
    Otsu, Satoshi
    Hirashima, Yoshinori
    Nishikawa, Kazuo
    Sakashita, Hiroyuki
    Morinaga, Ryotaro
    Watanabe, Koichiro
    Shirao, Kuniaki
    JAPANESE CLINICAL MEDICINE, 2014, 5 : 19 - 23
  • [32] Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
    Sofya Pintova
    Sirish Dharmupari
    Erin Moshier
    Nicole Zubizarreta
    Celina Ang
    Randall F. Holcombe
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 591 - 598
  • [33] Predictive factors for response to chemotherapy in colorectal cancer patients
    Vincenzi, B
    La Cesa, A
    Santini, D
    Schiavon, G
    Grilli, C
    Graziano, F
    Tonini, G
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 52 (01) : 45 - 60
  • [34] Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome
    Kein-Leong Yim
    Medical Oncology, 2012, 29 : 1796 - 1801
  • [35] Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials
    O'Neil, Bert H.
    Goldberg, Richard M.
    ONCOLOGIST, 2008, 13 (10) : 1074 - 1083
  • [36] Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes
    McWhirter, Derek
    Kitteringham, Neil
    Jones, Robert P.
    Malik, Hassan
    Park, Kevin
    Palmer, Daniel
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 (02) : 404 - 415
  • [37] Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome
    Yim, Kein-Leong
    MEDICAL ONCOLOGY, 2012, 29 (03) : 1796 - 1801
  • [38] Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer
    Diaz, Roberto
    Aparicio, Jorge
    Molina, Jorge
    Palomar, Laura
    Gimenez, Alejandra
    Ponce, Jose
    Segura, Angel
    Gomez-Codina, Jose
    MEDICAL ONCOLOGY, 2006, 23 (03) : 347 - 357
  • [39] Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer
    Des Guetz, G.
    Mariani, P.
    Cucherousset, J.
    Benamoun, M.
    Lagorce, C.
    Sastre, X.
    Le Toumelin, P.
    Uzzan, B.
    Perret, G.-Y.
    Morere, J.-F.
    Breau, J.-L.
    Fagard, R.
    Schischmanoff, P. O.
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2715 - 2719
  • [40] Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
    Pintova, Sofya
    Dharmupari, Sirish
    Moshier, Erin
    Zubizarreta, Nicole
    Ang, Celina
    Holcombe, Randall F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 591 - 598
12345